{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:44:08Z","timestamp":1793166248444,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mutations in the drug binding region of BCR-ABL lead to imatinib resistance during the management of chronic myeloid leukemia (CML). In our study, 62 Philadelphia positive (Ph<jats:sup>+<\/jats:sup>) CML patients showing conspicuous expression of BCR-ABL gene were treated with imatinib. At the end of 3 months, 21\/62 (33.87%) patients did not obtain complete hematological response (CHR) and also showed no significant decrease in BCR-ABL gene expression. In all the imatinib-resistant patients BCR-ABL gene was PCR amplified and sequenced. The sequence analysis showed four novel missense mutations p.(Leu301Ile), p.(Tyr320His), p.(Glu373Asp), p.(Asp381Asn) and six already reported mutations p.(Val256Gly), p.(Thr315Ile), p.(Gly250Glu), p.(Tyr253His), p.(Phe317Leu), p.(Met351Thr) which contributed in the formation of inactive enzyme and also two novel frameshift mutations p.(Glu281*) and p.(Tyr393*), which resulted in truncated protein formation. Further, the structural analysis revealed all these mutations affected P-loop, gatekeeper, catalytic and activation loop domain regions of the enzyme causing poor imatinib binding in the ATP region. The primary intention of the study was to find out the mutations in the BCR-ABL gene causing imatinib resistance. This study highlights the need for BCR-ABL gene sequence analysis to detect the mutations in CML patients in order to properly guide the therapy.<\/jats:p>","DOI":"10.1038\/s41598-019-38672-x","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T11:12:27Z","timestamp":1550661147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients"],"prefix":"10.1038","volume":"9","author":[{"given":"Chodimella","family":"Chandrasekhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasupuleti Santhosh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9991-0773","authenticated-orcid":false,"given":"Potukuchi Venkata Gurunadha Krishna","family":"Sarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"key":"38672_CR1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1126\/science.3460176","volume":"233","author":"Y Ben-Neriah","year":"1986","unstructured":"Ben-Neriah, Y. et al. The chronic myelogenous leukemia- specific P210 protein is the product of the bcr\/abl hybrid gene. Science. 233, 212\u2013214 (1986).","journal-title":"Science."},{"key":"38672_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.leukres.2013.12.025","volume":"38","author":"MH Elias","year":"2014","unstructured":"Elias, M. H. et al. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome. Leuk Res. 38, 454\u2013459 (2014).","journal-title":"Leuk Res."},{"key":"38672_CR3","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford, S. et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 99, 3472\u20133475 (2002).","journal-title":"Blood."},{"key":"38672_CR4","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","volume":"102","author":"S Branford","year":"2003","unstructured":"Branford, S. et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 102, 276\u2013283 (2003).","journal-title":"Blood."},{"key":"38672_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/j.1460-2075.1989.tb03397.x","volume":"8","author":"P Jackson","year":"1989","unstructured":"Jackson, P. & Baltimore, D. N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J. 8, 449\u2013456 (1989).","journal-title":"EMBO J."},{"key":"38672_CR6","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0969-2126(96)00116-5","volume":"4","author":"HJ Nam","year":"1996","unstructured":"Nam, H. J. et al. Intra molecular interactions of the regulatory domains of the Bcr-Abl kinase reveal a novel control mechanism. Structure. 4, 1105\u20131114 (1996).","journal-title":"Structure."},{"key":"38672_CR7","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley, G. Q., Van Etten, R. A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science. 247, 824\u2013830 (1990).","journal-title":"Science."},{"key":"38672_CR8","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","volume":"106","author":"SG Willis","year":"2005","unstructured":"Willis, S. G. et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 106, 2128\u20132137 (2005).","journal-title":"Blood."},{"key":"38672_CR9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/nsb0894-546","volume":"1","author":"A Musacchio","year":"1994","unstructured":"Musacchio, A., Saraste, M. & Wilmanns, M. High-resolution crystal structures of tyrosine kinase SH3 domains complexed with proline rich peptides. Nat Struct Biol. 1, 546\u2013551 (1994).","journal-title":"Nat Struct Biol."},{"key":"38672_CR10","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/0092-8674(92)90437-H","volume":"70","author":"M Overduin","year":"1992","unstructured":"Overduin, M. et al. Three-dimensional solution structure of the Src homology 2 domain of c-Abl. Cell. 70, 697\u2013704 (1992).","journal-title":"Cell."},{"key":"38672_CR11","doi-asserted-by":"publisher","first-page":"e0114828","DOI":"10.1371\/journal.pone.0114828","volume":"10","author":"S Vaidya","year":"2015","unstructured":"Vaidya, S. et al. Evolution of BCR\/ABL gene mutation in CML is time dependent and dependent on the pressure exerted by tyrosine kinase inhibitor. PLoS One. 10, e0114828 (2015).","journal-title":"PLoS One."},{"key":"38672_CR12","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","volume":"15","author":"D Milojkovic","year":"2009","unstructured":"Milojkovic, D. & Apperley, J. Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia. Clin Cancer Res. 15, 7519\u20137527 (2009).","journal-title":"Clin Cancer Res."},{"key":"38672_CR13","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani, M. et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 27, 6041\u20136051 (2009).","journal-title":"J Clin Oncol."},{"key":"38672_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000330607","volume":"127","author":"F Stagno","year":"2012","unstructured":"Stagno, F. et al. Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia. Acta Haematol. 127, 7\u20139 (2012).","journal-title":"Acta Haematol."},{"key":"38672_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000210060","volume":"121","author":"W Ma","year":"2009","unstructured":"Ma, W. et al. BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors. Acta Haematol. 121, 27\u201331 (2009).","journal-title":"Acta Haematol."},{"key":"38672_CR16","first-page":"1022","volume":"2","author":"S Kimura","year":"2014","unstructured":"Kimura, S., Ando, T. & Kojima, K. BCR-ABL Point Mutations and TKI Treatment in CML Patients. J Hematol Transfus. 2, 1022 (2014).","journal-title":"J Hematol Transfus."},{"key":"38672_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4103\/0971-5851.133707","volume":"35","author":"P Deb","year":"2014","unstructured":"Deb, P. et al. Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate. Indian J Med Paediatr Oncol. 35, 26\u201330 (2014).","journal-title":"Indian J Med Paediatr Oncol."},{"key":"38672_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4103\/0971-5916.93423","volume":"135","author":"MS Anand","year":"2012","unstructured":"Anand, M. S. et al. Cytogenetic & molecular analyses in adult chronic myelogenous leukaemia patients in north India. Indian J Med Res. 135, 42\u201348 (2012).","journal-title":"Indian J Med Res."},{"key":"38672_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4103\/0971-6866.132758","volume":"20","author":"Z Iqbal","year":"2014","unstructured":"Iqbal, Z. A comprehensive analysis of breakpoint cluster region-abelson fusion oncogene splice variants in chronic myeloid leukemia and their correlation with disease biology. Indian J Hum Genet. 20, 64\u201368 (2014).","journal-title":"Indian J Hum Genet."},{"key":"38672_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4103\/ijmpo.ijmpo_80_17","volume":"39","author":"S Kagita","year":"2018","unstructured":"Kagita, S. et al. Assessment of BCR-ABL1 fusion transcripts and their association with response to imatinib treatment in chronic myeloid leukemia patients. Indian J Med Paediatr Oncol. 39, 165\u2013171 (2018).","journal-title":"Indian J Med Paediatr Oncol."},{"key":"38672_CR21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1590\/S1415-47572010005000037","volume":"33","author":"EA Osman","year":"2010","unstructured":"Osman, E. A. et al. Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients. Genet Mol Biol. 33, 229\u2013231 (2010).","journal-title":"Genet Mol Biol."},{"key":"38672_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00277-009-0822-7","volume":"89","author":"P Sharma","year":"2010","unstructured":"Sharma, P. et al. Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts. Ann Hematol. 89, 241\u2013247 (2010).","journal-title":"Ann Hematol."},{"key":"38672_CR23","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.leukres.2011.05.015","volume":"35","author":"R Latagliata","year":"2011","unstructured":"Latagliata, R. et al. Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant\/intolerant to imatinib. Leuk Res. 35, 1164\u20131169 (2011).","journal-title":"Leuk Res."},{"key":"38672_CR24","doi-asserted-by":"publisher","first-page":"19585","DOI":"10.1074\/jbc.271.32.19585","volume":"271","author":"PB Allen","year":"1996","unstructured":"Allen, P. B. & Wiedemann, L. M. An activating mutation in the ATP binding site of the ABL kinase domain. J Biol Chem. 271, 19585\u201319591 (1996).","journal-title":"J Biol Chem."},{"key":"38672_CR25","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1074\/jbc.M109.039206","volume":"285","author":"H Yuan","year":"2010","unstructured":"Yuan, H. et al. BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. J Biol Chem. 285, 5085\u20135096 (2010).","journal-title":"J Biol Chem."},{"key":"38672_CR26","doi-asserted-by":"publisher","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","volume":"65","author":"DJ Barnes","year":"2005","unstructured":"Barnes, D. J. et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 65, 8912\u20139 (2005).","journal-title":"Cancer Res."},{"key":"38672_CR27","unstructured":"Shaffer, L. G., Slovak, M. L. & Campbell, L. J. ISCN 2009: An International System for Human Cytogenetic Nomenclature. S. Karger AG, Basel (2009)."},{"key":"38672_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.gene.2014.03.049","volume":"542","author":"D Joshi","year":"2014","unstructured":"Joshi, D. et al. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR\/ABL positive CML patients. Gene. 542, 109\u2013112 (2014).","journal-title":"Gene."},{"key":"38672_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.bbrc.2018.09.090","volume":"505","author":"PS Kumar","year":"2018","unstructured":"Kumar, P. S. et al. In vitro large scale production of megakaryocytes to functional platelets from human hematopoietic stem cells. Biochem Biophys Res Commun. 505, 168\u2013175 (2018).","journal-title":"Biochem Biophys Res Commun."},{"key":"38672_CR30","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","volume":"13","author":"JJ van Dongen","year":"1999","unstructured":"van Dongen, J. J. et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 13, 1901\u201328 (1999).","journal-title":"Leukemia."},{"key":"38672_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.gene.2014.05.037","volume":"546","author":"SK Pasupuleti","year":"2014","unstructured":"Pasupuleti, S. K. et al. Novel frame shift mutations (\u2018A\u2019 deletion) observed in exon 9 of Wilms\u2019 tumor (WT1) gene in a patient reported with glomerulosclerosis. Gene. 546, 63\u201367 (2014).","journal-title":"Gene."},{"key":"38672_CR32","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","volume":"112","author":"S Branford","year":"2008","unstructured":"Branford, S. et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 112, 3330\u20138 (2008).","journal-title":"Blood."},{"key":"38672_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes, T. et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 108, 28\u201337 (2006).","journal-title":"Blood."},{"key":"38672_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cyto.2017.07.003","volume":"99","author":"PP Babu","year":"2017","unstructured":"Babu, P. P. et al. Novel mutations in the exon 5, intron 2 and 3\u2032 UTR regions of IL-12B gene were observed in clinically proven tuberculosis patients of south India. Cytokine. 99, 50\u201358 (2017).","journal-title":"Cytokine."},{"key":"38672_CR35","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.1093\/nar\/25.24.4876","volume":"25","author":"JD Thompson","year":"1997","unstructured":"Thompson, J. D., Gibson, T. J. & Plewniak, F. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25, 4876\u20134882 (1997).","journal-title":"Nucleic Acids Res."},{"key":"38672_CR36","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/bab.1209","volume":"61","author":"NK Yellapu","year":"2014","unstructured":"Yellapu, N. K. et al. Identification and analysis of novel R308K mutation in glucokinase of type 2 diabetic patient and its kinetic correlation. Biotechnol Appl Biochem. 61, 572\u2013581 (2014).","journal-title":"Biotechnol Appl Biochem."},{"key":"38672_CR37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4103\/0975-7406.135246","volume":"6","author":"PS Kumar","year":"2014","unstructured":"Kumar, P. S. et al. In silico designing and molecular docking of a potent analog against Staphylococcus aureus porphobilinogen synthase. J Pharm Bioallied Sci. 6, 158\u2013166 (2014).","journal-title":"J Pharm Bioallied Sci."},{"key":"38672_CR38","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1080\/07391102.2014.999704","volume":"33","author":"PS Kumar","year":"2015","unstructured":"Kumar, P. S. et al. Mutations in exons 3 and 7 resulting in truncated expression of human ATP6V1B1 gene showing structural variations contributing to poor substrate binding-causative reason for distal renal tubular acidosis with sensorineural deafness. J Biomol Struct Dyn. 33, 2094\u20132103 (2015).","journal-title":"J Biomol Struct Dyn."},{"key":"38672_CR39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/nar\/29.1.221","volume":"29","author":"RA Laskowski","year":"2001","unstructured":"Laskowski, R. A. PDBsum: Summaries and analyses of PDB structures. Nucleic Acids Res. 29, 221\u2013222 (2001).","journal-title":"Nucleic Acids Res."},{"key":"38672_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-13-S4-S2","volume":"13","author":"E Bramucci","year":"2012","unstructured":"Bramucci, E. et al. PyMod: sequence similarity searches, multiple sequence-structure alignments, and homology modeling within PyMOL. BMC Bioinformatics. 13, S2 (2012).","journal-title":"BMC Bioinformatics."},{"key":"38672_CR41","doi-asserted-by":"crossref","unstructured":"Adzhubei, I., Jordan, D. M., & Sunyaev, S. R. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet, Chapter 7: Unit7.20 (2013).","DOI":"10.1002\/0471142905.hg0720s76"},{"key":"38672_CR42","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1093\/nar\/gkg509","volume":"31","author":"PC Ng","year":"2003","unstructured":"Ng, P. C. & Henikoff, S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812\u20133814 (2003).","journal-title":"Nucleic Acids Res."},{"key":"38672_CR43","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ejmg.2016.05.009","volume":"59","author":"BS Kumar","year":"2016","unstructured":"Kumar, B. S. et al. Identification of novel mutations in CD2BP1 gene in clinically proven rheumatoid arthritis patients of south India. Eur J Med Genet. 59, 404\u2013412 (2016).","journal-title":"Eur J Med Genet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-38672-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-38672-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-38672-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T06:11:37Z","timestamp":1671257497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-38672-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["38672"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-38672-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,20]]},"assertion":[{"value":"12 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"2412"}}